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Introduction
Cannabis use has proliferated since ancient times. It is currently the 
most commonly used illicit drug that affects human psychological 
health. Many clinical trials have shown that cannabis is a gateway 
drug to use of other substances and has comorbidity with other 
psychiatric disorders, especially schizophrenia1-6. The psychosocial 
treatment models for cannabis dependence include motivational 
enhancement therapy, cognitive behavioral therapy and contingency 
management for adults. 
In addition, brief strategic family therapy, family behavior 
therapy, family support network intervention and community 
reinforcement approach counseling, functional family therapy, 
multidimensional family therapy, and multisystemic therapy are 
other psychosocial treatment models for youths7. 
Only 29% of cannabis dependent individuals seek treatment8, 
yet significant decreases in cannabis use are seen in 31-36% of 
individuals that seek treatment9,10. Follow-up studies have found 
that over 60% in substance use disorders end in relapse, leading 
to potentially chronic and relapsing cases11-13. Treatment models 
have been developed to prevent relapse. However, clinical data has 
shown that treatments used in substance use disorders provide far 
from satisfactory results14. Although cognitive behavioral therapy15 
shows significant short-term effects on many substance users, 50-70% 
relapse ratio is still a serious problem of this therapy model16. New 
and effective therapies should be researched in order to increase the 
success of relapse prevention treatments15.
In 2004, Hayes17 described the third wave of cognitive behavioral 
therapies17 as mindfulness-based therapies; new research and 
applications using mindfulness concepts are being developed for 
substance use disorders18. Although there are multiple definitions, 
mindfulness is commonly defined as the capacity to place one’s 
attention and focus on the present moment in a non-judgmental, 
non-reactive, and compassionate manner19-22. Mindfulness has 
been described as a capacity that is present since birth and that 
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can be developed by meditation practices and mindfulness-based 
interventions19,23,24. Mindfulness-based relapse prevention (MBRP)25, 
a new treatment model, has been recently developed; this model 
combines mindfulness meditation and cognitive-behavioral relapse 
prevention techniques26. The mindfulness practices of MBRP aim to 
increase an individual’s awareness of external triggers and internal 
cognitive and affective processes; increase the ability to tolerate 
challenging cognitive, affective, and physical experiences25; and 
enhance metacognitive abilities27. Recent studies suggest several 
possible mechanisms about mindfulness based interventions in 
addictive behaviours. Neurobiological mechanisms in areas associated 
with craving, negative affect, and substance use relapse may be affected 
by mindfulness training, altering basic neurobiological processes 
related to reactive behaviors. Data from clinical trials likewise 
suggest mindfulness training may lead to decreases in self-reported 
severity of factors related to relapse such as anxiety, depression, and 
stress, decreases in both craving  and reactivity to craving and an 
improved ability to decouple the drinking impulse from drinking 
behavior28. Recent theories have emphasized the multi-dimensional 
nature of dependence and how it is influenced by positive/negative 
reinforcement and automaticity. Indeed, mindfulness is thought to be 
linked with dependence by enhancing attention control and reducing 
automaticity. Tiffany’s cognitive processing model of addiction is an 
important theory that describes the relationship between mindfulness 
and substance use. This theory outlines how routine behaviors, 
including substance use, become automatic over time and thus 
difficult to refrain from; continued use or relapse stems from the 
inability to disrupt these automatic behavioral routines29. 
The negative reinforcement model of relapse suggests that 
negative sensations are the most powerful motivator of chronic 
substance use. According to this model, individuals use substances 
to avoid aversive moods, such as anxiety and depression30. This 
theory intersects with the self-medication theory that suggests that 
individuals use substances to avoid aversive experiences and sustain 
positive experiences31. 
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The effect of MBRP and modified MBRP protocols in substance 
use disorders was evaluated in four independent research studies. 
MBRP treatment was reported to decrease substance use or 
events related with substance use, such as cravings and responses 
to substance triggers27,32-35. Some researchers have proposed that 
mindfulness reduces the necessarity of avoiding aversive sensations 
by increasing positive sensations and reducing negative sensations36-38.
Trait Mindfulness has been thought to be a naturally occurring 
difference among individuals or a dispositional trait24 that can be 
developed through meditative practices and mindfulness-based 
interventions19,23. Individuals with high levels of trait mindfulness 
are theorized to be better able to view aversive experiences as being 
transient and to be less likely to engage in substance use behaviors 
as a means of coping with such experiences20,39,40.
Based on this information, we hypothesized that the level of 
trait mindfulness of individuals are positively related with their 
capacity to quit cannabis use and negatively related with their severity 
of cannabis dependence. In this study we aimed to evaluate the 
relationship between trait mindfulness level and cannabis use of two 
groups during the follow up period; group continue (GC) and group 
quit (GQ). In addition, we analyzed the relationship between trait 
mindfulness and severity of cannabis dependence in both groups.
Methods
Participants
Outpatients that were sent to our treatment center by the probation 
office were under probation due to illegal substance use and were 
involved in the study after signing an informed consent form. The 
patients were between 18–65 years old, could write and read and were 
diagnosed with cannabis dependence according to the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition – Text 
Revision (DSM IV-TR). The study ran from 01 January 2014 to 31 
March 2014 at the Department for the Treatment of Alcohol and 
Substance Use Disorders of Ankara Numune Education and Research 
Hospital. Patients with educational and language problems that 
prevented diagnostic psychiatric interviews, another axis-I diagnosis 
other than cannabis dependence, diagnosis of mental disorder due 
to general medical conditions, or mental retardation were excluded. 
The approval for the study was obtained on 18 December 2013 from 
the Presidential Ethics Committee of Ankara Numune Education 
and Research Hospital (decision number 70/2013).
Measures
After the patients signed informed consent and accepted participation 
in the study, sociodemographic data on patients were recorded. 
To measure the dependence severity, the participants were asked 
to fill out the Addiction Profile Index (API) developed by Kultegin 
Ogel, Cuneyt Evren, Figen Karadag and Defne Tamar Gurol. The 
API consists of the following five subscales of substance use: the 
characteristics of substance use, dependency diagnosis, the effects 
of substance use on the user, cravings, and motivation to quit using 
substances41. The API total scores are divided into three categories 
that describe the severity of dependence: a) < 12 points indicate low 
dependence, b) 12-14 points indicate moderate dependence, and 
c) > 14 points indicate high dependence41. The participants were 
also asked to self-asses themselves on the Mindfulness Attention 
and Awareness Scale (MAAS). This scale, developed by Brown and 
Ryan24, evaluates the level of mindfulness and consists of 15 items; 
high resulting values indicate a high level of mindfulness. The mean 
MAAS value of the whole sample was accepted as the determining 
threshold of high and low mindfulness. A validity and reliability study 
was conducted according to the Turkish study by Zumra Ozyesil et 
al.42. The MAAS measures only the “acting with awareness” facet 
of mindfulness; without “observing”, “describing” and “accepting 
without judgement” facets. In addition to the sociodemographic 
data and the calculated API and MAAS scales, urine tests of cannabis 
metabolites were performed to evaluate cannabis use. All these tests 
were completed in the first meeting, after which the follow-up period 
began. The follow-up period consisted of 3 meetings during the 
six weeks after the first meeting, as one meeting every two weeks. 
In all meetings, urine tests were repeated. During the follow-up 
period, mindfulness-based interventions were not conducted with 
the sample.
Procedures
We followed up patients diagnosed with cannabis dependence for 
six weeks following diagnosis. The individuals involved in the study 
were further divided into two groups at the end of the follow-up 
period based on the results of the urine test of cannabis metabolites. 
During follow-up, excluding the first meeting, individuals with at least 
one positive urine test were included in Group Continue (GC), and 
individuals with negative tests were included in Group Quit (GQ). 
We aimed to evaluate the relationship between trait mindfulness level 
and cannabis use of two groups. At the beginning of the study, 190 
cannabis dependent-patients were undergoing treatment at our study 
center, although 2 patients could not read or write, 4 patients refused 
to join, and 20 patients could not complete the follow-up period and 
were thus excluded. In total, 164 individuals were included in the study. 
Only male patients were included, as no female patients diagnosed 
with cannabis dependence visited our center during the study period.
Data analysis
We evaluated the relationship between dependence severity and 
trait mindfulness cross sectionally at the first meeting and followed 
up the patients for six weeks to assess the relationship between 
trait mindfulness and cannabis use by repeated urine tests. All 
statistical analyses were conducted with IBM SPSS for Windows, 
version 21.0. Numerical variables were summarized as the mean 
± standard deviation; categoric variables were summarized as 
numbers and percentages. Parametric hypothesis tests (normality 
and homogeneity of variances) were performed before comparison 
of the groups to test if their variances were equal. To determine 
differences in the numerical variables of the two independent groups, 
a t-test was applied for parametric data. The Kruskal Wallis test was 
also applied; this test is used for comparing groups of two or more 
independent samples. The relationship between numerical variables 
was determined by calculating the Pearson correlation coefficients. 
The significance level was determined as p < 0.05. The relationship 
between cannabis dependence severity and trait mindfulness of 
two groups (GC and GQ) were analyzed by t test. The relationship 
between API total score and MAAS scores in the whole sample 
analyzed by pearson correlation coefficient. The relationship between 
API-subgroups and trait mindfulness in the whole sample was 
analyzed by kruskal wallis test.
Results
In our study, GC was composed of 79 patients who tested positive 
for cannabis in at least one of their urine samples (excluding the first 
meeting) during the 6-week follow-up period. GQ was composed of 
85 patients who quit substance use during the follow-up period and 
thus qualified as early partial/full remission candidates; none of their 
urine tests (excluding the first meeting) were positive for cannabis.
The mean age of GC was 29.1 ± 8.5 and of GQ was 26.7 ± 
7.0. All patients were male. No significant differences were found 
between two groups in regard to the sociodemographic data on age, 
marital status, educational level, living situation, and job status in 
the previous year.
Fifty-two individuals (65.8%) in GC considered cannabis to be 
a problem in their life in comparison with 45 individuals (52.9%) in 
GQ; the difference in this parameter was not statistically significant 
(Table 1). Fourteen individuals (17.7%) in GC had a history of legal 
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problems related with cannabis use in comparison with 5 individuals 
(5.9%) in GQ; this difference was statistically significant, with a greater 
ratio of individuals experiencing legal problems in GC (Table 1).
Table 1. Comparison of group continue and group quit due to having history 
of legal problems depending on cannabis use and thinking cannabis use 
is a problem 
Group 
Continue
(n = 79)
Group 
Quit
(n = 85)
p*
I have lived legal problems depending 
on cannabis use
14 (17.7%) 5 (5.9%) 0.034
Cannabis use is a problem in my life 52 (65.8%) 45 (65.8%) 0.228
p*: p value obtained bay applying chi-square test.
The relationship between level of trait mindfulness and history 
of using substances other than cannabis was examined for the whole 
sample; trait mindfulness level was significantly lower in the group 
that had history of using substances other than cannabis (Table 2).
 
Table 2. The relationship between MAAS score and history of substance 
use other than cannabis ın whole sample 
Do not have history of 
substance use other than 
cannabis
(n = 48)
Have history of substance 
use other than cannabis
(n = 116)
p*
MAAS
(Ave ± SD)
76.0 ± 12.8 69.6 ± 15.2 0.012
MAAS: Mindfulness Attention Awareness Scale. 
*: p value obtained by applying t test.
Ave: average; SD: standard deviation.
Statistically significant differences were found between GC 
and GQ in the total API scores of the subscales of substance use 
characteristics, dependence diagnoses, effects of substance use on the 
user, and cravings. These values were higher in GC than GQ (Table 3).
In addition, the MAAS score was statistically higher in GQ in 
comparison with GC (p < 0.001) (Table 3).
There was a negative relationship between the total API and 
MAAS scores for the whole sample. As the API score increased, the 
MAAS score decreased (p < 0.001) (Table 4).
The patients were divided into three groups based on their 
API scores of dependence severity: low, moderate or high. As API 
scores increased from low to high, the MAAS score demonstrated a 
corresponding decrease (Table 5). Upon comparing the API groups 
given their total MAAS scores, significant differences were found 
between API groups of low and high severity (p < 0.001) and between 
the groups of moderate and high severity (p < 0.05), although no 
significant difference was found between the groups of low and 
moderate severity.
Table 4. API total score and MAAS total score relationship ın the whole sample
r* p
MAAS total -0.456 < 0.001
API: Addiction Profile Index; MAAS: Mindfulness Attention Awareness Scale.
r*: pearson correlation coefficient.
Table 5. The Relationship Between API-subgroups and Mindfulness
API low
 (n = 17)
API moderate 
(n = 48)
API high
 (n = 99)
p*
MAAS total
Median [Min-Max]
83 [60 – 90] 81 [38 – 90] 75 [36 – 90] < 0,001
p*: p value obtained by appealing Kruskal Wallis. 
MAAS: Mindfulness Attention Awareness Scale; API: Addiction Profile Index.
Discussion
To our knowledge, this is the first study in literature to evaluate 
the relationship between the level of trait mindfulness, severity of 
cannabis dependence and capacity to quit cannabis use. During 
the follow-up period of our study, we found that the level of trait 
mindfulness was significantly higher in GQ, or those that quit 
cannabis use, in comparison with GC, composed of individuals 
that tested positive for cannabis in at least one drug test. This result 
is consistent with other research studies that have reported that 
higher levels of mindfulness are negatively related with substance use 
frequency43,44. All individuals are born with the capacity to exercise 
mindfulness, although they may possess varying levels of the trait. 
Trait mindfulness may be an important determining factor of the 
ability to quit substance use and achieve remission. Furthermore, 
when we compared the relationship between level of trait mindfulness 
and history of use of substances other than cannabis across the 
whole sample, trait mindfulness was significantly lower in the 
group with history of using substances other than cannabis. Mixed 
substance abuse can result in serious problems, such as suicide45. 
Mindfulness-based interventions are reported to reduce alcohol and 
other substance use/abuse cases14.
We found a statistically significant relationship between trait 
mindfulness and dependence severity. In the whole sample, as 
the mindfulness level lowered, the severity of dependence level 
increased. Similar with our data, Vidrine et al.46 reported higher 
mindfulness levels in nicotine-dependent individuals with lower 
dependence severities. Other studies have reported that individuals 
with high dependence severity have more problems in social, work 
and family life47,48, and more intensive treatment and support are 
needed in these cases49. This evidences that increasing mindfulness 
may correlate with decreasing dependence severity and other 
problems caused by substance dependence. In the other hand high 
dependence severity level is related with severe chronic substance 
use; the level of mindfulness might have been decreased as substance 
Table 3. Comparison of API subscales’ values. API total values. MAAS total values between the groups
Group Continue (n = 79) Group Quit (n = 85) p*
Ave ± SD Median [Min – Max] Ave ± SD Median [Min – Max]
The characteristic of substance use 5.4 ± 0.3 5.4 [4.3 – 6.4] 4.9 ± 0.7 5.3 [2.3 – 6.9] < 0.001
Dependency diagnosis 21.9 ± 1.8 21.5 [18 – 29] 21.1 ± 1.4 21 [13 – 23.5] 0.018
The effects of substance use on the user 26.3 ± 7.1 24 [11 – 48] 22.1 ± 4.9 20 [15 – 37] < 0.001
Cravings 9.8 ± 2.9 9 [4 – 19] 7.7 ± 2.1 8 [4 – 13] < 0.001
Motivation to quit using substances 11.6 ± 2.9 12 [5 – 15] 10.8 ± 3.6 12 [3 – 16] 0.216
API total 15.3 ± 2.0 13.7 ± 1.8 < 0.001
MAAS total 69.4 ± 15.3 74 [36 – 90] 78.4 ± 10.7 80 [46 – 90] < 0.001
API: Addiction Profile Index; MAAS: Mindfulness Attention Awareness Scale. 
*: p value obtained by applying t test.
Ave: average; SD: standard deviation.
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use might negatively influence attention and awareness. We divided 
our sample into three groups according to dependence severity as 
scored by the API: low, moderate, and high. As API scores increased 
from low to high, MAAS scores significantly decreased. There were 
significant differences between API groups of low and high severity 
(p < 0.001) and between groups of moderate and high severity 
(p < 0.05); however, no significant difference was found between 
groups of low and moderate severity. This may be indicating that 
individuals with low and moderate dependence could benefit from 
similar interventions, yet highly dependent individuals may need 
more intensive interventions. Additional complications and loss 
of functionality are observed in individuals with high levels of 
dependence, and treating this group is more difficult. Increasing levels 
of mindfulness may be an important, effective and new treatment 
model for individuals with high dependence in order to encourage 
abstinence and reduce the severity of substance dependence.
We found that the API scores considering substance use 
characteristics, dependence diagnosis, effects of substance use on 
the user, and cravings were statistically significantly lower for GQ 
than GC. Furthermore, the prevalence of substance abuse and 
associated life problems, history of legal problems, level of substance 
dependence, and effects of substance use on the user were all lower 
in GQ in comparison with GC; these results are consistent with the 
nature of dependence. Cravings is another parameter that results 
in incompliance with treatment and relapse during treatment of 
substance dependence50-52. In our study, cravings were higher in GC 
than GQ. These findings were consistent with the studies of Bowen 
et al. (2009) and Vidrine et al. (2009) that focused on the relationship 
between different aspects of mindfulness and substance use. The 
severity of cravings may be decreased by increasing an individual’s 
level of mindfulness. This finding may imply that mindfulness-based 
treatments could be proposed as new and effective treatment models 
for cannabis dependence.
It seems to be a paradox that the ratio of individuals that consider 
cannabis use to be a problem is not statistically significantly different 
between in GC and GQ, even though the level of mindfulness of 
GC was significantly lower than GQ. GC also reported a statistically 
higher history of legal problems, which could be explaining this result. 
Limitations
In the study period, no female individuals with cannabis dependence 
were involved, so the relationship between gender and level of 
mindfulness could not be evaluated. The API scale was a self-
reported scale, and this may be one limitation of our study. MAAS 
was the only scale used to measure mindfulness in our study, based 
on a Turkish validity and reliability search. MAAS measures acting 
with awareness, only one component of mindfulness, so this may 
be another limitation. The data in our study were collected cross-
sectionally, yet whether or not mindfulness-based treatment methods 
could improve mindfulness levels or provide benefits in cannabis-
dependent patients is unable to be directly determined.
Assessed for eligibility (n = 190)
Excluded (n = 26)
 – Not meeting inclusion criteria (n = 2)
 – Declined to participate (n = 4)
 – Other reasons (n = 20)
Included (n = 164)
(First meeting)
 – Sociodemographic datas 
 – Addiction Profile Index Scale 
 – Mindfulness Attention and 
Awareness Scale
 – Urine cannabis metabolite analysis
Six week Follow-up Period
 – Urine Cannabis Metabolite Analysis
 – No mindfulness based interventions 
were conducted
Inclusion criteria
 – 18-65 years old
 – Diagnosed with “Cannabis 
Dependence” due to DSM IV-TR
Group-Continue (n = 79)
 – Continued to use substance, as at 
least one of their urine cannabis 
metabolite analysis result was 
positive except first one during six 
weeks follow-up period
Exclusion criteria
 – Having educational and language 
problems that prevent diagnostic 
psychiatric interview
 – Having another axis-1 diagnosis 
except “cannabis dependence”
 – Having diagnosis of mental disorder 
due to general medical condition
 – Mental retardation
Group-Quit (n = 85 )
 – Quitted substance use during follow-up 
period
 – Early full/partial remission candidates, 
 – None of their urine cannabis metabolite 
analysis result was positive (excluding 
the first one)
Enrollment
Follow-Up
Analysis
Figure 1. Flow diagram of the study.
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Recommendations
As we determined the negative relation between trait mindfulness 
level and cannabis use behavior, this may encourage the expansion of 
mindfulness based interventions in cannabis dependence. Also long-
term follow-up studies are needed to evaluate if chronic substance 
use decrease mindfulness levels of individuals. In addition further 
cross-sectional and follow up studies are needed in substance use 
disorders other than cannabis which evaluate the effect of trait 
mindfulness on treatment results. 
References
1.  Breakey WR, Goodell H, Lorenz PC, McHugh PR. Hallucinogenic drugs 
as precipitants of schizophrenia. Psychol Med. 1974;4(3):255-61. 
2.  Caspari D. Cannabis and schizophrenia: results of a follow-up study. Eur 
Arch Psychiatry Clin Neurosci. 1999;249(1):45-9. 
3.  Halikas JA, Goodwin DW, Guze SB. Marihuana use and psychiatric 
illness. Arch Gen Psychiatry. 1972;27(2):162-5. 
4.  Hal l  W, Solowij  N.  Adverse ef fects  of  cannabis .  Lancet . 
1998;352(9140):1611-6. 
5.  Ögel K, Uğuz S, Sir A, Yenilmez Ç, Tamar M, Çorapçioğlu A, et al. 
Türkiye» De İlköğretim Ve Ortaöğretim Gençliği Arasında Esrar 
Kullanım Yaygınlığı. J Dependence. 2003;4:15-9. 
6.  Tennant FS, Groesbeck CJ. Psychiatric effects of hashish. Arch Gen 
Psychiatry. 1972;27(1):133-6. 
7.  Budney AJ, Vandrey RG, Stanger C. [Pharmacological and psychosocial 
interventions for cannabis use disorders]. Rev Bras Psiquiatr. 2010;32 
Suppl 1: S46-55.
8.  Agosti V, Levin FR. Predictors of treatment contact among individuals 
with cannabis dependence. Am J Drug Alcohol Abuse. 2004;30(1):121-7. 
9.  Carroll KM, Easton CJ, Nich C, Hunkele KA, Neavins TM, Sinha R, et 
al. The use of contingency management and motivational/skills-building 
therapy to treat young adults with marijuana dependence. J Consult Clin 
Psychol. 2006;74(5):955-66. 
10.  Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana 
dependence: a test of the relapse prevention model. J Consult Clin 
Psychol. 1994;62(1):92-9. 
11.  Connors GJ, Maisto SA, Donovan DM. Conceptualizations of relapse: 
a summary of psychological and psychobiological models. Addiction. 
1996;91(12s1):5-14. 
12.  Dixon L, McNary S, Lehman AF. Remission of substance use disorder 
among psychiatric inpatients with mental illness. Am J Psychiatry. 
1998;155(2):239-43. 
13.  McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, 
a chronic medical illness: implications for treatment, insurance, and 
outcomes evaluation. JAMA. 2000;284(13):1689-95. 
14.  Chiesa A, Serretti A. Are mindfulness-based interventions effective for 
substance use disorders? A systematic review of the evidence. Subst Use 
Misuse. 2014;49(5):492-512. 
15.  Irvin JE, Bowers CA, Dunn ME, Wang MC. Efficacy of relapse prevention: 
a meta-analytic review. J Consult Clin Psychol. 1999;67(4):563-70. 
16.  McHugh RK, Hearon BA, Otto MW. Cognitive behavioral therapy for 
substance use disorders. Psychiatr Clin North Am. 2010;33(3):511-25. 
17.  Hayes SC. Acceptance and commitment therapy, relational frame theory, 
and the third wave of behavioral and cognitive therapies. Behav Ther. 
2004;35(4):639-65. 
18.  Çatak PD, Ögel K. Farkindalik temelli terapiler ve terapötik süreçler. 
Klinik Psikiyatri. 2010;13:85-91. 
19.  Baer RA. Measuring mindfulness. Contemporary Buddhism. 
2011;12(1):241-61. 
20.  Kabat-Zinn J. Mindfulness-based interventions in context: past, present, 
and future. Clin Psychol Sci Pract. 2003;10(2):144-56. 
21.  Kabat-Zinn J. Wherever you go, there you are: mindfulness meditation 
in everyday life. Hyperion; 1994. 316 p. 
22.  Karyadi KA, VanderVeen JD, Cyders MA. A meta-analysis of the 
relationship between trait mindfulness and substance use behaviors. 
Drug Alcohol Depend. 2014;143:1-10. 
23.  Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L. Using self-report 
assessment methods to explore facets of mindfulness. Assessment. 
2006;13(1):27-45. 
24.  Brown KW, Ryan RM. The benefits of being present: mindfulness and its 
role in psychological well-being. J Pers Soc Psychol. 2003;84(4):822-48. 
25.  Bowen S, Chawla N, Marlatt GA. Mindfulness-based relapse prevention 
for the treatment of substance-use disorders: A clinician’s guide. New 
York, NY: Guilford Press; 2010. 
26.  Marlatt GA, Donovan DM. Relapse prevention: maintenance strategies 
in the treatment of addictive behaviors.New York: Guilford Press; 1985.
27.  Teasdale JD, Moore RG, Hayhurst H, Pope M, Williams S, Segal ZV. 
Metacognitive awareness and prevention of relapse in depression: 
empirical evidence. J Consult Clin Psychol. 2002;70(2):275-87. 
28.  Bowen S, Enkema MC. Relationship between dispositional mindfulness 
and substance use: findings from a clinical sample. Addict Behav. 
2014;39(3):532-7.
29.  Tiffany ST. A cognitive model of drug urges and drug-use behavior: role 
of automatic and nonautomatic processes. Psychol Rev. 1990;97(2):147-68. 
30.  Baker TB, Morse E, Sherman JE. The motivation to use drugs: a 
psychobiological analysis of urges. Nebr Symp Motiv. 1986;34:257-323.
31.  Khantzian EJ. The self-medication hypothesis of addictive disorders: focus 
on heroin and cocaine dependence. Am J Psychiatry. 1985;142(11):1259-64. 
32.  Bowen S, Witkiewitz K, Chawla N, Grow J. Integrating mindfulness 
meditation and cognitive behavioral traditions for the long-term 
treatment of addictive behaviors. JCOM. 2011;18(10):473-9. 
33.  Brewer JA, Sinha R, Chen JA, Michalsen RN, Babuscio TA, Nich C, 
et al. Mindfulness training and stress reactivity in substance abuse: 
Results from a randomized, controlled stage I pilot study. Subst Abus. 
2009;30(4):306-17. 
34.  Vieten C, Astin JA, Buscemi R, Galloway GP. Development of an 
acceptance-based coping intervention for alcohol dependence relapse 
prevention. Subst Abus. 2010;31(2):108-16. 
35.  Zgierska A, Rabago D, Zuelsdorff M, Coe C, Miller M, Fleming M. 
Mindfulness meditation for alcohol relapse prevention: a feasibility pilot 
study. J Addict Med. 2008;2(3):165-73. 
36.  Baer RA. Mindfulness training as a clinical intervention: A conceptual 
and empirical review. Clin Psychol Sci Pract. 2003;10(2):125-43. 
37.  Breslin FC, Zack M, McMain S. An information-processing analysis of 
mindfulness: Implications for relapse prevention in the treatment of 
substance abuse. Clin Psychol Sci Pract. 2002;9(3):275-99. 
38.  Shapiro SL, Carlson LE, Astin JA, Freedman B. Mechanisms of 
mindfulness. J Clin Psychol. 2006;62(3):373-86. 
39.  Brewer JA, Bowen S, Smith JT, Marlatt GA, Potenza MN. Mindfulness-
based treatments for co-occurring depression and substance use disorders: 
what can we learn from the brain? Addiction. 2010;105(10):1698-706. 
40.  de Dios MA, Herman DS, Britton WB, Hagerty CE, Anderson BJ, Stein 
MD. Motivational and mindfulness intervention for young adult female 
marijuana users. J Subst Abuse Treat. 2012;42(1):56-64.
41.  Ögel K, Evren C, Karadağ F, Gürol T. Bağimlilik Profil İndeksi’nin 
(BAPİ) Geliştirilmesi, Geçerlik ve Güvenilirliği. Türk Psikiyatri Dergisi. 
2012;23(4):264-73. 
42.  Özyeşil Z, Aslan C, Kesici Ş, ve Deniz ME. Bilinçli farkındalık ölçeği’ni 
Türkçeye uyarlama çalışması. Eğitim ve Bilim. 2011;36(160):224-35. 
43.  Black DS, Sussman S, Johnson CA, Milam J. Trait mindfulness helps shield 
decision-making from translating into health-risk behavior. J Adolesc 
Health. 2012;51(6):588-92. 
44.  Bramm SM, Cohn AM, Hagman BT. Can Preoccupation with alcohol 
override the protective properties of mindful awareness on problematic 
drinking? Addict Disord Their Treat. 2013;12(1):19-27. 
45.  Ögel K, Karali A, Tamar D, Çakmak D. Alkol Ve Madde El Kitabi. 
Bakırköy Ruh ve Sinir Hastalikları Hastanesi; 1998.
46.  Vidrine JI, Businelle MS, Cinciripini P, Li Y, Marcus MT, Waters AJ, et 
al. Associations of mindfulness with nicotine dependence, withdrawal, 
and agency. Subst Abus. 2009;30(4):318-27. 
47.  Calsyn DA, Saxon AJ, Bush KR, Howell DN, Baer JS, Sloan KL, et 
al. The Addiction Severity Index medical and psychiatric composite 
scores measure similar domains as the SF-36 in substance-dependent 
veterans: concurrent and discriminant validity. Drug Alcohol Depend. 
2004;76(2):165–171. 
48.  Richter D, Eikelmann B, Berger K. Use of the SF-36 in the evaluation of 
a drug detoxification program. Qual Life Res. 2004;13(5):907-14. 
49.  McLellan AT, Woody GE, Metzger D, McKay J, Durell J, Alterman AI, 
et al. Evaluating the effectiveness of addiction treatments: reasonable 
expectations, appropriate comparisons. Milbank Q. 1996;74(1):51-85. 
144 Paltun SC et al. / Arch Clin Psychiatry. 2017;44(6):139-44
50.  Bowen S, Marlatt A. Surfing the urge: brief mindfulness-based 
intervention for college student smokers. Psychol Addict Behav. 
2009;23(4):666-71. 
51.  Hartz DT, Frederick-Osborne SL, Galloway GP. Craving predicts use 
during treatment for methamphetamine dependence: a prospective, 
repeated-measures, within-subject analysis. Drug Alcohol Depend. 
2001;63(3):269-76. 
52.  Shiffman S, Gwaltney CJ, Balabanis MH, Liu KS, Paty JA, Kassel JD, et al. 
Immediate antecedents of cigarette smoking: an analysis from ecological 
momentary assessment. J Abnorm Psychol. 2002;111(4):531-45. 
